Opto Biosystems

Rewiring cancer treatment

What is the Challenge?

Aggressive cancers, such as glioblastoma, present significant treatment challenges, with survival rates remaining alarmingly low. Traditional therapies often fail to effectively target these malignancies, leading to poor patient outcomes. Additionally, the lack of real-time biomarkers hampers the ability to monitor disease progression and treatment efficacy, limiting personalized treatment approaches.

What is the Solution?

Opto.Bio is a pioneer of minimally invasive therapeutic neurotechnology which can track and treat disease electrically. They are using these devices within oncology to treat cancers. Their flagship platform, SOMA-1, consists of tiny, flexible neural implants capable of both sensing and stimulating electrical activity within the body. By leveraging advanced neural biomarkers and electrotherapies, Opto aims to enhance the treatment of hard-to-treat diseases, including aggressive cancers such as glioblastoma.

The SOMA-1 device operates wirelessly and conforms to the body’s natural tissue properties, ensuring patient comfort and safety. Its ability to provide real-time, on-demand electrophysiological data empowers clinicians with unprecedented insights into disease states and treatment responses. This innovative approach holds the potential to improve survival rates and quality of life for patients battling some of the most challenging cancers.

Latest